Haematologica (Apr 2019)
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target
- Maria Rosaria Sapienza,
- Francesco Abate,
- Federica Melle,
- Stefania Orecchioni,
- Fabio Fuligni,
- Maryam Etebari,
- Valentina Tabanelli,
- Maria Antonella Laginestra,
- Alessandro Pileri,
- Giovanna Motta,
- Maura Rossi,
- Claudio Agostinelli,
- Elena Sabattini,
- Nicola Pimpinelli,
- Mauro Truni,
- Brunangelo Falini,
- Lorenzo Cerroni,
- Giovanna Talarico,
- Rossana Piccioni,
- Stefano Amente,
- Valentina Indio,
- Giuseppe Tarantino,
- Francesco Brundu,
- Marco Paulli,
- Emilio Berti,
- Fabio Facchetti,
- Gaetano Ivan Dellino,
- Francesco Bertolini,
- Claudio Tripodo,
- Raul Rabadan,
- Stefano A. Pileri
Affiliations
- Maria Rosaria Sapienza
- Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy
- Francesco Abate
- Department of Systems Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA;Department of Biomedical Informatics, Columbia University College of Physicians and Surgeons, New York, NY, USA
- Federica Melle
- Division of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy
- Stefania Orecchioni
- Laboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
- Fabio Fuligni
- Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
- Maryam Etebari
- Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy
- Valentina Tabanelli
- Division of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy
- Maria Antonella Laginestra
- Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy
- Alessandro Pileri
- Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy;Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Italy
- Giovanna Motta
- Division of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy
- Maura Rossi
- Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy
- Claudio Agostinelli
- Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy
- Elena Sabattini
- Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy
- Nicola Pimpinelli
- Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Italy
- Mauro Truni
- Pathological Anatomy Histology & Cytogenetics, Niguarda Cancer Center, Niguarda-Ca' Granda Hospital, Milan, Italy
- Brunangelo Falini
- Institute of Hematology and Center for Hemato-Oncology Research (CREO), University and Hospital of Perugia, Italy
- Lorenzo Cerroni
- Universitätsklinik für Dermatologie und Venerologie, LKHUniversitatsklinikum Graz, Austria
- Giovanna Talarico
- Laboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
- Rossana Piccioni
- Department of Experimental Oncology, European Institute of Oncology, Milan, Italy
- Stefano Amente
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples ‘Federico II’, Italy
- Valentina Indio
- "Giorgio Prodi" Cancer Research Center, University of Bologna, Italy
- Giuseppe Tarantino
- "Giorgio Prodi" Cancer Research Center, University of Bologna, Italy
- Francesco Brundu
- Department of Systems Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA
- Marco Paulli
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS San Matteo Policlinic, Pavia, Italy
- Emilio Berti
- Department of Dermatology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinic and Milan University, Milan, Italy
- Fabio Facchetti
- Pathology Section, Department of Molecular and Translational Medicine, University of Brescia, Italy
- Gaetano Ivan Dellino
- Department of Experimental Oncology, European Institute of Oncology, Milan, Italy;Department of Oncology and Hemato-Oncology, University of Milan, Italy
- Francesco Bertolini
- Laboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
- Claudio Tripodo
- Tumor Immunology Unit, Department of Health Science, Human Pathology Section, University of Palermo School of Medicine, Italy
- Raul Rabadan
- Department of Systems Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA;Department of Biomedical Informatics, Columbia University College of Physicians and Surgeons, New York, NY, USA
- Stefano A. Pileri
- Division of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy
- DOI
- https://doi.org/10.3324/haematol.2018.202093
- Journal volume & issue
-
Vol. 104,
no. 4
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective therapy. In order to identify genetic alterations useful for a new treatment design, we used whole-exome sequencing to analyze 14 BPDCN patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program to be the most significantly undermined (P
